Celgene (CELG) Gross Profit Margin starting from the third quarter 2019 to third quarter 2018, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Celgene Corp  (NASDAQ: CELG)


Celgene's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CELG Gross Profit Margin (Sep 30 2019)
Q3 		(Jun 30 2019)
Q2 		(Mar 31 2019)
Q1 		(Dec 31 2018)
Q4 		(Sep 30 2018)
Q3
Y / Y Revenue Change 16.14 %
Seq. Revenue Change 2.73 %
Revenue In Millions $4,520.00
Gross Profit Margin 96.31 %
Gross Profit Margin Total Ranking # 124
Gross Profit In Millions $4,353.00
Y / Y Gross Profit Change 16.55 %
Seq. Gross Profit Change 2.45 %


Commenting Third Quarter 2019 Gross Profit Margin
Celgene has managed to improve its Revenue sequentially to $4,520.00 millions by 2.73 % faster than Gross Profit increase of 2.45 % to $4,353.00 millions, this led to contraction in Gross Profit Margin to 96.31 %, but the Celgene III. Quarter Gross Profit Margin remained above company average rate of 92.36%.


Observing third quarter 2019 results within Major Pharmaceutical Preparations industry 15 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 124, from total ranking in the previous quarter at 126.
Learn about Gross Margin
CELG's Gross Profit Margin third quarter 2019 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 16
Healthcare Sector # 20
Overall # 119

Gross Profit Margin Statistics
High Average Low
96.7 % 92.36 % 82.09 %
(Jun 30 2018)   (Sep. 30, 2005)


CELG Gross Income Trends • More of CELG's Profitabilty Ratios • CELG Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
CELG's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
CELG's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for CELG's Competitors
Gross Profit Margin Profit Margin for Celgene's Suppliers
Gross Profit Margin Profit Margin for CELG's Customers

You may also want to know
CELG's Annual Growth Rates CELG's Profitability Ratios CELG's Asset Turnover Ratio CELG's Dividend Growth
CELG's Roe CELG's Valuation Ratios CELG's Financial Strength Ratios CELG's Gross Profit Growth
CELG's Roa CELG's Inventory Turnover Ratio CELG's Growth Rates CELG's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2019, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2019 MRQ Gross ProfitSep 30 2019 MRQ Revenue
Ayala Pharmaceuticals Inc   100.00 %$ 0.001  Millions$ 0.001  Millions
Lexicon Pharmaceuticals Inc   99.80 %$ 293.871  Millions$ 294.448  Millions
Nabriva Therapeutics Plc  99.78 %$ 6.905  Millions$ 6.920  Millions
Ironwood Pharmaceuticals inc   99.61 %$ 130.661  Millions$ 131.167  Millions
Ionis Pharmaceuticals Inc   99.42 %$ 166.925  Millions$ 167.892  Millions
Intercept Pharmaceuticals inc   99.21 %$ 61.463  Millions$ 61.950  Millions
Omeros Corporation  99.07 %$ 29.578  Millions$ 29.856  Millions
Rigel Pharmaceuticals Inc  98.51 %$ 20.547  Millions$ 20.857  Millions
Agios Pharmaceuticals Inc   98.49 %$ 25.631  Millions$ 26.024  Millions
Corcept Therapeutics Inc  98.22 %$ 80.054  Millions$ 81.505  Millions
Vaccinex Inc   98.02 %$ 0.396  Millions$ 0.404  Millions
Skinvisible Inc   97.79 %$ 0.011  Millions$ 0.011  Millions
Acadia Pharmaceuticals Inc   97.45 %$ 92.170  Millions$ 94.586  Millions
Emmaus Life Sciences Inc   97.07 %$ 5.906  Millions$ 6.084  Millions
Travere Therapeutics Inc   96.59 %$ 42.860  Millions$ 44.373  Millions
Celgene Corp  96.31 %$ 4,353.000  Millions$ 4,520.000  Millions
Sage Therapeutics Inc   96.16 %$ 3.433  Millions$ 3.570  Millions
Assertio Holdings inc   95.93 %$ 52.904  Millions$ 55.147  Millions
Ptc Therapeutics inc   95.79 %$ 68.410  Millions$ 71.416  Millions
Verastem Inc   95.66 %$ 8.640  Millions$ 9.032  Millions
Supernus Pharmaceuticals inc   95.28 %$ 97.321  Millions$ 102.140  Millions
Regeneron Pharmaceuticals Inc   94.34 %$ 1,932.500  Millions$ 2,048.400  Millions
Therapeuticsmd Inc   93.91 %$ 22.275  Millions$ 23.720  Millions
Adamas Pharmaceuticals Inc  93.33 %$ 13.004  Millions$ 13.933  Millions
Durect Corp  93.21 %$ 10.032  Millions$ 10.763  Millions
Portola Pharmaceuticals inc   92.71 %$ 34.115  Millions$ 36.799  Millions
Alnylam Pharmaceuticals Inc   92.56 %$ 64.848  Millions$ 70.061  Millions
Pfenex Inc   92.50 %$ 14.105  Millions$ 15.248  Millions
Alexion Pharmaceuticals Inc   92.46 %$ 1,167.900  Millions$ 1,263.100  Millions
Karyopharm Therapeutics Inc   92.30 %$ 12.136  Millions$ 13.149  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.